An Alternative Alcobra (ADHD) Trade
Research - Alcobra Pharma (ADHD) announced on September 19 that all scheduled follow-up visits had been complete in the company’s phase 3 clinical trial of metadoxine in … Continue Reading
Premium: Read NowResearch
Why Conatus Fell Out of Bed in the Second Half
Research - The recent decline in the price of Conatus Pharmaceuticals (CNAT) mirrors the pullback in small-cap stocks, though CNAT fell out of favor in-part due to the delay of … Continue Reading
Premium: Read Now
Arrowhead Research: Know This Ahead of November
Research - Arrowhead Research (ARWR) is a name we’ve been stalking since the company released initial data from a phase 2a study of ARC-520, a candidate for the treatment of hepatitis B infection.
Premium: Read Now
Medivation: Strong XTANDI Performance Warrants Continued Exposure
Research - We’ve considered Medivation (MDVN) a long-term play on the clinical and commercial strength of XTANDI (enzalutamide), which with the aid of Astellas (ALPMY) is well on its way toward … Continue Reading
Premium: Read Now
The Approval Decision for Orexigen Isn’t Cut and Dry
Research - Orexigen Therapeutics (OREX) is trading at $6.00 this afternoon, one week ahead of the September 11 FDA approval decision for Contrave (NB32). We suggested buying OREX in late July at $5.20 as … Continue Reading
Premium: Read Now
Paying Up for Illumina’s Growth was the Right Move 140 Points Ago; It Still Is
Research - For long-term PropThink subscribers, few investments have yielded higher profits than Illumina (ILMN). Since our initiation of coverage in November 2012, shares of the San Diego-based company … Continue Reading
Premium: Read Now
Booking Gains on Keryx and What to Look for Next
Research - Why we're booking gains on Keryx (KERX) and an options strategy for the Sept. 7 PDUFA decision on Zerenex.
Read Now